G protein‐coupled receptor‐mediated signaling of immunomodulation in tumor progression DOI Creative Commons
Guang‐Hong Qiu, Bin Yu, Mei Ma

et al.

The FASEB Journal, Journal Year: 2024, Volume and Issue: 38(14)

Published: July 17, 2024

G protein-coupled receptors (GPCRs) are essential contributors to tumor growth and metastasis due their roles in immune cell regulation. Therefore, GPCRs potential targets for cancer immunotherapy. Here, we discuss the current understanding of signaling pathways progression from an immunocellular perspective. Additionally, focus on regulating checkpoint proteins involved evasion. Finally, review progress clinical trials GPCR-targeted drugs treatment, which may be combined with immunotherapy improve treatment efficacy. This expanded role shed light mechanisms underlying provide a novel perspective

Language: Английский

The role of CXCL family members in different diseases DOI Creative Commons
Chenjia Zhou, Ying Gao,

Peilun Ding

et al.

Cell Death Discovery, Journal Year: 2023, Volume and Issue: 9(1)

Published: July 1, 2023

Chemokines are a large family mediating lot of biological behaviors including chemotaxis, tumor growth, angiogenesis and so on. As one member this family, CXC subfamily possesses the same ability. chemokines can recruit migrate different categories immune cells, regulate tumor's pathological like proliferation, invasion metastasis, activate angiogenesis, etc. Due to these characteristics, CXCL is extensively closely associated with tumors inflammatory diseases. studies becoming more intensive, CXCLs' concrete roles better described, therapeutic applications biomarkers targets also deeply explained. In review, role members in various diseases summarized.

Language: Английский

Citations

93
CXCL8 in Tumor Biology and Its Implications for Clinical Translation DOI Creative Commons
Xingyu Xiong, Xinyang Liao, Shi Qiu

et al.

Frontiers in Molecular Biosciences, Journal Year: 2022, Volume and Issue: 9

Published: March 15, 2022

The chemokine CXCL8 has been found to play an important role in tumor progression recent years. activates multiple intracellular signaling pathways by binding its receptors (CXCR1/2), and plays dual pro-tumorigenic roles the microenvironment (TME) including directly promoting survival affecting components of TME indirectly facilitate progression, which include facilitating cell proliferation epithelial-to-mesenchymal transition (EMT), pro-angiogenesis, inhibit anti-tumor immunity. More recently, clinical trials indicate that can act as independently predictive biomarker patients receiving immune checkpoint inhibitions (ICIs) therapy. Preclinical studies also suggest combined blockade ICIs therapy enhance efficacy, several are being conducted evaluate this modality.

Language: Английский

Citations

81
CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications DOI Creative Commons
Yaru Yang, Jiayan Li,

Wangrui Lei

et al.

International Journal of Biological Sciences, Journal Year: 2023, Volume and Issue: 19(11), P. 3341 - 3359

Published: Jan. 1, 2023

Cancer is a multi-step disease caused by the accumulation of genetic mutations and/or epigenetic changes, and biggest challenge around world.Cytokines, including chemokines, exhibit expression changes disorders in all human cancers.These cytokine abnormalities can disrupt homeostasis immune function, make outstanding contributions to various stages cancer development such as invasion, metastasis, angiogenesis.Chemokines are superfamily small molecule chemoattractive cytokines that mediate variety cellular functions.Importantly, interactions chemokine members CXCL12 its receptors CXCR4 CXCR7 have broad impact on tumor cell proliferation, survival, angiogenesis, microenvironment, thus participate onset many cancers leukemia, breast cancer, lung prostate multiple myeloma.Therefore, this review aims summarize latest research progress future challenges regarding role CXCL12-CXCR4/CXCR7 signaling axis highlights potential biomarker or therapeutic target for providing essential strategies novel targeted therapies.

Language: Английский

Citations

70
Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment DOI

Paniz Siminzar,

Mohammad Reza Tohidkia, Elisabeth Eppard

et al.

Molecular Imaging and Biology, Journal Year: 2022, Volume and Issue: 25(3), P. 464 - 482

Published: Dec. 14, 2022

Language: Английский

Citations

55
New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine DOI Creative Commons
Hanli Xu, Shuye Lin, Ziyun Zhou

et al.

Cellular and Molecular Immunology, Journal Year: 2023, Volume and Issue: 20(7), P. 739 - 776

Published: May 17, 2023

Abstract Over the past thirty years, importance of chemokines and their seven-transmembrane G protein-coupled receptors (GPCRs) has been increasingly recognized. Chemokine interactions with trigger signaling pathway activity to form a network fundamental diverse immune processes, including host homeostasis responses disease. Genetic nongenetic regulation both expression structure conveys chemokine functional heterogeneity. Imbalances defects in system contribute pathogenesis variety diseases, cancer, inflammatory metabolic neurological disorders, which render focus studies aiming discover therapies important biomarkers. The integrated view biology underpinning divergence plasticity provided insights into dysfunction disease states, including, among others, coronavirus 2019 (COVID-19). In this review, by reporting latest advances results from analyses plethora sequencing-based datasets, we outline recent understanding genetic variations heterogeneity provide an updated contribution pathophysiological network, focusing on chemokine-mediated inflammation cancer. Clarification molecular basis dynamic chemokine-receptor will help advance achieve precision medicine application clinic.

Language: Английский

Citations

32
Application of oncolytic virus in tumor therapy DOI
Zhijian Huang,

Hongen Guo,

Lin Lin

et al.

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(4)

Published: April 1, 2023

Abstract Oncolytic viruses (OVs) can selectively kill tumor cells without affecting normal cells, as well activate the innate and adaptive immune systems in patients. Thus, they have been considered a promising measure for safe effective cancer treatment. Recently, few genetically engineered OVs developed to further improve effect of elimination by expressing specific regulatory factors thus enhance body's antitumor immunity. In addition, combined therapies other immunotherapies applied clinical. Although there are many studies on this hot topic, comprehensive review is missing illustrating mechanisms clearance how modify their effects. study, we provided OVs. reviewed with including radiotherapy CAR‐T or TCR‐T cell therapy. The useful generalize usage OV

Language: Английский

Citations

26
The lipid-metabolism enzyme ECI2 reduces neutrophil extracellular traps formation for colorectal cancer suppression DOI Creative Commons
Lixia Chen,

Peiling Dai,

Lei Liu

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Aug. 21, 2024

Abnormalities in ether lipid metabolism as well the formation of neutrophil extracellular traps have recently been recognized detrimental factors affecting tumorigenesis and progression. However, role abnormal colorectal cancer (CRC) evolution has not reported. Here we show that metabolism-related gene enoyl-CoA δ-isomerase 2 (ECI2) plays a tumor-suppressor CRC is negatively associated with poor prognosis patients. We mechanistically demonstrate ECI2 reduces lipid-mediated Interleukin 8 (IL-8) expression leading to decreased recruitment for suppression. In particular, inhibits production cells by inhibiting peroxisomal localization alkylglycerone phosphate synthase (AGPS), rate-limiting enzyme synthesis. These findings only deepen our understanding metabolic reprogramming interactions progression CRC, but also provide ideas identifying potential diagnostic markers therapeutic targets CRC. The association between rewiring tumour microenvironment shown be relevant Here, authors ether-lipid generation

Language: Английский

Citations

9
Targeting autophagy and lipid metabolism in cancer stem cells DOI

Bandana Chakravarti,

Jawed A. Siddiqui, Rohit A. Sinha

et al.

Biochemical Pharmacology, Journal Year: 2023, Volume and Issue: 212, P. 115550 - 115550

Published: April 13, 2023

Language: Английский

Citations

17
Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer DOI
Sunil Kumar, Sounok Sengupta, Iqra Ali

et al.

Journal of Biomolecular Structure and Dynamics, Journal Year: 2023, Volume and Issue: 41(21), P. 11353 - 11372

Published: April 28, 2023

Epidermal growth factor receptor (EGFR) enhances lung cancer development, due to their inability permeate the cell membrane, secreted factors work through specialized signal transduction pathways. The purpose of this study is find out a novel anticancer agent that inhibits EGFR and reduces chances cancer. A series triazole-substituted quinazoline hybrid compounds were designed by Chemdraw software docked against five different crystallographic tyrosine kinase domain (TKD). For docking visualization PyRx, Autodock vina, Discovery studio visualizer used. Molecule-14, Molecule-16, Molecule-19, Molecule-20, Molecule-38 showed significant affinity but Molecule-19 excellent binding (-12.4 kcal/mol) with kinase. superimposition co-crystalized ligand hit compound shows similar conformation at active site (PDB ID: 4HJO) indicating coupling pharmaceutically active. good bioavailability score (0.55) no sign carcinogenesis, mutagenesis, or reproductive toxicity properties. MD simulation MMGBSA represent stability free energy demonstrating (Molecule-19) may be used as lead compound. also ADME properties, scores, synthetic accessibility fewer signs toxicity. It was observed potential inhibitor side effects than reference molecule. Additionally, molecular dynamics revealed stable nature protein-ligand interaction provided information about amino acid residues involved in binding. Overall, led identification inhibitors favorable pharmacokinetic We believe outcome can help develop more potent drug-like molecules tackle human

Language: Английский

Citations

15
Biological Insight and Recent Advancement in the Treatment of Neuroblastoma DOI Open Access

Zoriamin Rivera,

Carlos Escutia,

Mary Beth Madonna

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(10), P. 8470 - 8470

Published: May 9, 2023

One of the most frequent solid tumors in children is neuroblastoma, which has a variety clinical behaviors that are mostly influenced by biology tumor. Unique characteristics neuroblastoma includes its early age onset, propensity for spontaneous tumor regression newborns, and high prevalence metastatic disease at diagnosis individuals older than 1 year age. Immunotherapeutic techniques have been added to previously enlisted chemotherapeutic treatments as therapeutic choices. A groundbreaking new treatment hematological malignancies adoptive cell therapy, specifically chimeric antigen receptor (CAR) T therapy. However, due immunosuppressive nature microenvironment (TME) tumor, this approach faces difficulties. Numerous tumor-associated genes antigens, including MYCN proto-oncogene (MYCN) disialoganglioside (GD2) surface antigen, found molecular analysis cells. The gene GD2 two useful immunotherapy findings neuroblastoma. cells devise numerous methods evade immune identification or modify activity In addition addressing difficulties potential advancements immunotherapies review attempts identify important immunological actors biological pathways involved dynamic interaction between TME system.

Language: Английский

Citations

13